Cove Street Capital on Viemed (VMD)

Episode Summary

Executive Summary: The episode analyzes Viemed (VMD), a small-cap provider of home non-invasive ventilators, as a high-growth, asset-light healthcare business with strong free cash flow and large runway. Cove Street argues VMD can compound through market share gains, refurbished equipment economics, and potential adjacent services, while acknowledging meaningful CMS/Medicare reimbursement risk and the possibility of future pricing cuts.

Main Topics: Business overview and investment case: Viemed is framed as the largest U.S. provider of non-invasive ventilators, operating an asset-light home-service model with strong margins, high FCF, and an estimated path to doubling EBITDA over the next few years. Clinical use case and market need: The discussion explains that NIVs primarily serve late-stage COPD patients, improving quality of life, reducing hospital visits, and lowering system-wide costs, which underpins demand despite the serious nature of the disease. Differentiated service model vs. legacy DME peers: Viemed is contrasted with broader durable medical equipment providers like Apria and Lincare. Its focus on a narrow patient set, physician education, RT-led service, and compliance support is presented as a key competitive advantage. CMS reimbursement and regulatory risk: A major portion of the episode examines Medicare/CMS pricing risk, including prior cuts, the 2016 reimbursement shock, and the possibility of future competitive bidding changes that could pressure the business. Economic durability and operating leverage: The speakers argue the market underappreciates the company’s unit economics, scale benefits, refurbishing/reuse model, and ability to continue growing while maintaining good returns on capital. Growth runway and adjacent expansion: Viemed has significant geographic and product expansion potential, including expansion into new states, higher patient penetration, additional respiratory products, and behavioral health-related services. COVID impact and post-pandemic recovery: COVID created a one-time equipment-sales boost and may have delayed organic patient growth by limiting hospital access, but it also helped build relationships and awareness that could support future growth.

Key Arguments: Viemed’s focused NIV model is more of a service business than a distributor business, which supports patient retention and physician relationships. The company serves a large addressable market relative to its current size, with only about 7,500 patients served versus roughly 1.25 million potential patients. CMS sets reimbursement rates, so VMD does not get paid more for better service, but its lower-cost, asset-light model lets it win share profitably at the same rates. NIVs have demonstrated healthcare-system savings by reducing emergency room visits and lowering annual cost per patient materially. The biggest risk is reimbursement cuts from CMS, but management and investors believe NIVs are more likely than other DME categories to be protected because they are life-extending and clinically effective. Scale matters because VMD can buy ventilators cheaper, refurbish them for reuse, and spread technician/route costs across more patients. The business has optionality beyond NIVs, including behavioral health services and other adjacent home-health devices or chronic-care services. COVID distorted recent results through one-time equipment sales, but also may have created a “loaded spring” as RTs and hospital relationships ramp back up. Despite reimbursement risk, the stock appears inexpensive relative to growth and FCF generation, which is why Cove Street frames it as a GARP idea rather than a deep-value story.

Data Points: Market capitalization: ~$300 million to $350 million - Described as a small-cap company at the start of the discussion. Current stock price: ~$10 - Referenced when discussing upside to the $18 target. Implied upside target: ~$18 - Cove Street’s medium-term estimate for the stock. Revenue at spin-out: $50 million - Company was spun out in 2017 from a TSX Ventures parent. Pre-COVID growth rate: ~40% per year - Management/investors highlighted strong organic growth before COVID. Patients served today: ~7,500 - Compared with the much larger addressable patient population. Potential patient market: ~1.25 million - Estimated total patient pool that could potentially be served. Late-stage COPD patients addressable: ~50% - Speakers said about half of late-stage COPD patients have chronic respiratory failure requiring this kind of care. Annual ER visit frequency without NIV: 4 to 6 times per year - Used to illustrate the burden on severe COPD patients before NIV treatment. Annual healthcare cost without NIV: $50,000 to $60,000 - Estimated cost to the system before NIV adoption. Annual healthcare cost with NIV: ~$12,000 - Estimated cost after putting patients on NIV. Risk reduction in hospitalizations: ~42% - Cited as a study result supporting efficacy and cost savings. Immediate reduction in risk of death: 38% - Used to argue NIV is more life-extending than standard quality-of-life devices. Bad debt as a percentage of revenue: ~6% to 10% (often ~10%) - Discussed as normal across DME businesses due to copays and lower-income patient demographics. Annual bad debt question: 1% to 2% would seem low to outsiders - Raised as a concern because of Medicare-heavy exposure. 2016 Medicare cut impact: EBITDA from $11 million to $2 million - Illustrated the severity of reimbursement cuts on the business. 2016 revenue impact: Revenue from $35 million to $27 million - Showed the topline effect of the Medicare cut. COVID equipment-sales bump: Major one-time spike in equipment sales - Attributed to hospitals buying ventilators during the early months of the pandemic. Licensing footprint: ~38 states - Viemed is licensed in most states, but not all are equally penetrated. Well-distributed states: ~20 states - Only about 20 states were described as meaningfully built out. Respiratory therapist staffing model: 1 RT can support startup operations in a new state - Used to illustrate the company’s asset-light expansion model. Equipment cost per ventilator: ~$6,000 - Referenced in the discussion of refurbishment and reuse economics.

Pivotal Quotes: "Viamed is the largest provider of non-invasive ventilators in the country." — Andrew Leaf: Core pitch describing the company’s market position and category leadership. "This is extending life. This is, they just came out with a study. There's a 38% immediate reduction in risk of death with NIV." — Andrew Leaf: Used to explain why CMS may treat NIV differently from other DME products. "We're not looking to invest at 80 times free cash flow on a 30, 40% grower of software. You know, this is more in our wheelhouse." — Andrew Leaf: Explains why the company fits Cove Street’s value/GARP discipline despite strong growth.

Implications: Listeners should see VMD as a high-growth, service-heavy healthcare compounder with substantial runway, but one that lives under the shadow of CMS reimbursement policy. If CMS remains stable, upside could be significant; if not, the low-cost, asset-light model may still help VMD outperform peers.